Abstract
Erectile dysfunction (ED) is a major health problem as the population ages. Basic science research for the last two decades has expanded the knowledge on ED and identified several key molecular changes associated with the pathogenesis of ED, including nitric oxide (NO) / cyclic guanosine monophosphate (cGMP) / protein kinase G (PKG) pathway, RhoA/Rho-associated protein kinase (ROCK) signaling pathway, reactive oxygen species (ROS), renin-angiotensin system (RAS) and tumor necrosis factor-alpha (TNF-α). The causes of ED are classified into aging, vasculogenic, neurogenic, endocrinological, drug-induced and psychogenic. ED is often associated with systemic diseases, such as diabetes and cardiovascular diseases. In this review, we will review the molecular mechanisms of ED and known mechanisms behind ED associated with systemic diseases.
Keywords: Angiotensin, erectile dysfunction, nitric oxide, pathophysiology, reactive oxygen species, RhoA/Rho-associated protein kinase, tumor necrosis factor-alpha.
Current Drug Targets
Title:Pathophysiology of Erectile Dysfunction
Volume: 16 Issue: 5
Author(s): Hotaka Matsui, Nikolai A. Sopko, Johanna L. Hannan and Trinity J. Bivalacqua
Affiliation:
Keywords: Angiotensin, erectile dysfunction, nitric oxide, pathophysiology, reactive oxygen species, RhoA/Rho-associated protein kinase, tumor necrosis factor-alpha.
Abstract: Erectile dysfunction (ED) is a major health problem as the population ages. Basic science research for the last two decades has expanded the knowledge on ED and identified several key molecular changes associated with the pathogenesis of ED, including nitric oxide (NO) / cyclic guanosine monophosphate (cGMP) / protein kinase G (PKG) pathway, RhoA/Rho-associated protein kinase (ROCK) signaling pathway, reactive oxygen species (ROS), renin-angiotensin system (RAS) and tumor necrosis factor-alpha (TNF-α). The causes of ED are classified into aging, vasculogenic, neurogenic, endocrinological, drug-induced and psychogenic. ED is often associated with systemic diseases, such as diabetes and cardiovascular diseases. In this review, we will review the molecular mechanisms of ED and known mechanisms behind ED associated with systemic diseases.
Export Options
About this article
Cite this article as:
Matsui Hotaka, A. Sopko Nikolai, L. Hannan Johanna and J. Bivalacqua Trinity, Pathophysiology of Erectile Dysfunction, Current Drug Targets 2015; 16 (5) . https://dx.doi.org/10.2174/138945011605150504114041
DOI https://dx.doi.org/10.2174/138945011605150504114041 |
Print ISSN 1389-4501 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-5592 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
An Updated Review of ISCOMSTM and ISCOMATRIXTM Vaccines
Current Pharmaceutical Design Hypoxia and Inflammation in Prostate Cancer Progression. Cross-talk with Androgen and Estrogen Receptors and Cancer Stem Cells
Endocrine, Metabolic & Immune Disorders - Drug Targets Effects of Physical Exercise on Depressive Symptoms and Biomarkers in Depression
CNS & Neurological Disorders - Drug Targets Pharmacomimetics of Exercise: Novel Approaches for Hippocampally- Targeted Neuroprotective Agents
Current Medicinal Chemistry Regulating miRNA by Natural Agents as a New Strategy for Cancer Treatment
Current Drug Targets The Role of Chromogranin A (CgA) in Monitoring Patients with Prostate Cancer Under Androgen Deprivation Therapy: Comparison with Prostatic Specific Antigen (PSA)
Current Radiopharmaceuticals Anticancer Alkylphospholipids: Mechanisms of Action, Cellular Sensitivity and Resistance, and Clinical Prospects
Current Pharmaceutical Design Molecular Targets of FTY720 (Fingolimod)
Current Molecular Medicine Improvement of Nonviral Gene Therapy by Epstein-Barr Virus (EBV)-based Plasmid Vectors
Current Gene Therapy In situ Generated <sup>212</sup>Pb-PSMA Ligand in a <sup>224</sup>Ra-Solution for Dual Targeting of Prostate Cancer Sclerotic Stroma and PSMA-positive Cells
Current Radiopharmaceuticals Subject Index To Volume 6
Endocrine, Metabolic & Immune Disorders - Drug Targets Evaluation of Multifunctional Hybrid Analogs for Stilbenes, Chalcones and Flavanones
Anti-Cancer Agents in Medicinal Chemistry Angiopoietin-2 Axis Inhibitors: Current Status and Future Considerations for Cancer Therapy
Current Angiogenesis (Discontinued) The Epigenetic Modification of Epigallocatechin Gallate (EGCG) on Cancer
Current Drug Targets Abelson Tyrosine-Protein Kinase 1 as Principal Target for Drug Discovery Against Leukemias. Role of the Current Computer-Aided Drug Design Methodologies
Current Topics in Medicinal Chemistry RAGE and RAGE Ligands in Cancer
Current Molecular Medicine Screening for Silent Coronary Artery Disease in Diabetics- or Not?
Current Diabetes Reviews Membrane Tyrosine Kinase Receptors are an Important Target for the Therapy of Acute Myeloid Leukemia
Current Cancer Therapy Reviews Nasal Drug Delivery System-Factors Affecting and Applications
Current Drug Therapy Anti-Cancer Potential of a Novel SERM Ormeloxifene
Current Medicinal Chemistry